Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive Insight discuss how a holistic, multi ...

The debate around terminally ill patients' access to experimental treatments appears to be coming to a head in the US, with growing discussion about federalising the Right-to-Try (RTT) laws.